Europe Molecular Diagnostics Market
                     Increasing Focus on Companion Diagnostics Creates an 
Opportunity for the Europe Molecular Diagnostics Market 
Molecular diagnostics is a branch of medical and clinical laboratory science 
that involves the detection, identification, and measurement of specific 
genetic or molecular markers within a person's biological samples (e.g., 
blood, tissue, or other bodily fluids) to diagnose and monitor diseases, 
predict disease risk, and guide treatment decisions. It is a rapidly evolving 
field that has revolutionized the way various diseases are diagnosed and 
managed. 
The growth of this market is driven by factors such as technological 
advancements in molecular diagnostics, the increasing use of PoC 
diagnostic tests, an increase in funding for the R&D of diagnostic products, 
the rising geriatric population, and the increasing prevalence of target 
diseases. However, unfavorable regulatory framework and cost of 
molecular diagnostic tests hamper the growth of this market to a notable 
extent. Additionally, developments in companion diagnostics are expected 
to offer significant growth opportunities for the players operating in the 
molecular diagnostics market. However, the dearth of skilled professionals 
is a challenging factor for the market. 
Download Free Report Sample 
Now: https://www.meticulousresearch.com/download-sample-
report/cp_id=5710  
Among the products & services included in the report, in 2023, the kits & 
reagents segment is expected to account for the largest share of the 
Europe molecular diagnostics market. Recurrent use of assays & kits in the 
detection of various diseases through molecular diagnostics, rise in 
product approvals, and technological advancements in molecular 
techniques contribute to the large market share of this segment. 
Among the test types included in the report, in 2023, the laboratory tests 
segment is expected to account for the largest share of the Europe 
molecular diagnostics market. Laboratory tests are traditionally used in 
hospitals and diagnostic centers and are widely accepted. The laboratory 
testing approach for molecular diagnostics has many advantages over 
other approaches. It has higher accuracy and reliability when compared to 
point-of-care testing. The laboratory equipment and analyzers have high 
sensitivity and specificity. Additionally, unlike point-of-care testing, the lab 
testing approach can be performed on all tests. Furthermore, the tests 
conducted in the lab testing approach are usually less expensive than their 
counterpart point-of-care tests. These factors contribute to the large 
market share of this segment. 
Browse in depth @ 
https://www.meticulousresearch.com/product/europe-molecular-
diagnostics-market-5710  
Among the technologies included in the report, in 2023, the polymerase 
chain reaction (PCR) segment is expected to account for the largest share 
of the Europe molecular diagnostics market. The specificity and sensitivity 
of the instrument and the technological developments in various 
diagnostic applications contribute to this segment's large market share. 
Also, there were new product launches during the COVID-19 pandemic 
due to increased demand for PCR kits. For instance, in August 2022, F. 
Hoffmann-La Roche Ltd (Switzerland) launched the Digital LightCycler 
System, a digital PCR system. It accurately quantifies trace amounts of 
specific DNA and RNA targets not typically detected by conventional PCR. 
Among the applications included in the report, in 2023, the infectious 
diseases segment is expected to account for the largest share of the 
Europe molecular diagnostics market. Infectious diseases are illnesses that 
can be transmitted from person to person, rapidly spreading in certain 
regions and giving rise to epidemics. Early diagnosing of these initial 
infections and preventing their further transmission through in vitro 
testing is important. The growing incidence of infectious diseases, 
increased investments in research related to infectious disease 
diagnostics, and the sudden emergence of a pandemic are the factors 
attributing to the large market share of this segment. 
Request to Sample Free Report: 
https://www.meticulousresearch.com/request-sample-
report/cp_id=5710  
Among the end users included in the report, in 2023, the hospitals & clinics 
segment is expected to account for the largest share of the Europe 
molecular diagnostics market. Increased hospitalizations due to various 
diseases, the high prevalence of healthcare-associated infections (HAIs), 
and the proliferation of hospitals and clinics in countries leading to growth 
in the utilization of molecular diagnostic products. Furthermore, the 
outbreak of the COVID-19 pandemic has resulted in an increased demand 
for molecular diagnostic kits in hospitals & clinics for the treatment and 
prevention of COVID-19 infections. 
Geographic Review: 
This research report analyzes major geographies in Europe, namely 
Germany, France, the U.K., Switzerland, Ireland, Belgium, Italy, Spain, and 
the Rest of Europe. In 2023, Germany is expected to account for the largest 
share of the Europe molecular diagnostics market. Some of the major 
factors contributing to the largest share include the rising incidence of 
chronic diseases, the aging population, efforts by the German Government 
to further improve the quality of healthcare, research for the development 
of new technologies, and a high number of patients suffering from 
hospital-acquired infections.  
Quick Buy @ 
https://www.meticulousresearch.com/Checkout/86927555 
Key Players 
The key players profiled in this market study are F. Hoffmann-La Roche Ltd 
(Switzerland), Hologic, Inc. (U.S.), QIAGEN N.V. (Netherlands), Danaher 
Corporation (U.S.), bioMérieux S.A. (France), Becton, Dickinson and 
Company (BD) (U.S.), Siemens Healthineers AG (Germany), DiaSorin S.p.A. 
(Italy), Abbott Laboratories (U.S.), Thermo Fisher Scientific Inc. (U.S.), Agilent 
Technologies, Inc. (U.S.), and Illumina, Inc. (U.S.). 
Contact: 
Mr. Khushal Bombe 
Meticulous Market Research Inc. 
1267 Willis St, Ste 200 Redding,  
California, 96001, U.S. 
USA: +1-646-781-8004 
Europe : +44-203-868-8738 
APAC: +91 744-7780008 
Email- [email protected]  
Visit Our Website: https://www.meticulousresearch.com/ 
Connect with us on   
LinkedIn- https://www.linkedin.com/company/meticulous-research